Close Menu

NEW YORK (GenomeWeb News) – Canadian molecular diagnostics firm Med BioGene said yesterday that it intends to file for an initial public offering "as soon as possible" in the US to support development and commercialization of its gene expression-based assay for early-stage non-small-cell lung cancer.

MBI, based in Vancouver, BC, said that it has retained the services of Rodman & Renshaw as lead underwriter for the IPO, and will float an unspecified number of common shares on the Nasdaq Capital Market.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.

A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.

Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.

In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.

Oct
21
Sponsored by
Agilent

Genomics is a key element in the potential of precision medicine to transform oncology. 

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.